Hologic, Inc. (NASDAQ:HOLX) Position Trimmed by LaFleur & Godfrey LLC

LaFleur & Godfrey LLC cut its position in Hologic, Inc. (NASDAQ:HOLX) by 0.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 146,587 shares of the medical equipment provider’s stock after selling 1,100 shares during the quarter. Hologic accounts for about 1.8% of LaFleur & Godfrey LLC’s portfolio, making the stock its 22nd largest holding. LaFleur & Godfrey LLC owned about 0.05% of Hologic worth $7,095,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. American Century Companies Inc. acquired a new position in Hologic in the 4th quarter valued at approximately $104,871,000. Norges Bank acquired a new position in Hologic in the 4th quarter valued at approximately $75,662,000. Oregon Public Employees Retirement Fund increased its position in Hologic by 3,960.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 1,192,649 shares during the period. State of Tennessee Treasury Department increased its position in Hologic by 338.4% in the 4th quarter. State of Tennessee Treasury Department now owns 699,514 shares of the medical equipment provider’s stock valued at $28,750,000 after acquiring an additional 539,968 shares during the period. Finally, Vanguard Group Inc increased its position in Hologic by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 28,259,273 shares of the medical equipment provider’s stock valued at $1,158,065,000 after acquiring an additional 303,902 shares during the period. Institutional investors own 90.39% of the company’s stock.

HOLX opened at $45.50 on Friday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.02 and a current ratio of 1.45. Hologic, Inc. has a 1-year low of $37.03 and a 1-year high of $48.82. The firm has a market cap of $12.09 billion, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 2.16 and a beta of 0.71.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, May 1st. The medical equipment provider reported $0.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.01. The firm had revenue of $818.40 million for the quarter, compared to the consensus estimate of $806.99 million. Hologic had a negative net margin of 0.32% and a positive return on equity of 26.73%. The business’s revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.53 earnings per share. On average, equities research analysts anticipate that Hologic, Inc. will post 2.42 earnings per share for the current year.

In related news, insider Benjamin Jordan Cohn sold 6,830 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $46.70, for a total transaction of $318,961.00. Following the completion of the sale, the insider now owns 22,002 shares in the company, valued at $1,027,493.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter J. Valenti III sold 4,242 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $47.38, for a total transaction of $200,985.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,378 shares of company stock valued at $1,105,836. 0.90% of the stock is currently owned by corporate insiders.

HOLX has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a research note on Thursday. ValuEngine lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Piper Jaffray Companies upped their price objective on shares of Hologic to $49.00 and gave the company an “overweight” rating in a research note on Thursday, January 31st. BidaskClub lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, TheStreet lowered shares of Hologic from a “b” rating to a “c+” rating in a research note on Wednesday, May 1st. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. Hologic has a consensus rating of “Hold” and an average target price of $45.41.

WARNING: This piece of content was originally posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/hologic-inc-holx-stake-lowered-by-lafleur-godfrey-llc.html.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: Quiet Period Expirations

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.